Approaching the Patient Adherence challenge in an era with higher stakes, digital enablement, and deeper patient understanding
Speaker: Jeff Hewitt, MBA
Date/Time: Friday October 21st, 2016, 8:00-10:00 AM (PST), presentation begins at 8:30 sharp
Place: Genentech, Room 42-1D
475 East Grand Avenue
South San Francisco, 94080
Pricing: Free, but online registration is required by October 18th, 2016
Jeff Hewitt is a partner in the Health Practice of A.T. Kearney where he focuses upon helping life sciences companies make significant transformations, improve decision-making, and invest strategically. This includes assisting over a dozen major life sciences companies improve their R&D decision-making and innovation capabilities through major transformations of process, governance, analytics, and culture. Engagements have included development investment capability building, cross-therapeutic area strategy, pipeline assessments, external assessments of value, and cost-saving clinical trial optimization.
Over twenty years he has supported well more than 100 client engagements across a variety of strategic topics such as franchise strategy, drug development, Healthcare Reform, US market pricing strategy, and patient adherence solutions. He has a B.A. in Economics and English from Amherst College and an M.B.A from Stanford University. He is based in A.T. Kearney’s San Francisco office.
The patient adherence challenge isn’t new. Healthcare providers, pharmacists, and pharmaceutical companies have been trying to get patients to take their medicines for decades. However, it’s different today. Why is it different? Life-saving specialty medicines come with high prices and high expectations, a broad collection of digital enabled tools and technologies are available, and our understanding of why patients don’t adhere has improved significantly. These changes create the opportunity for the industry to do better. This talk will address:
The changes that suggest the Patient Adherence challenge should be viewed differently today
The reasons that patients don’t adhere
What we can learn from adherence solutions in the market today
A framework for designing adherence solutions
An argument for why building this capability is valuable